respiratory distress News
-
Ony Cares For Kids Too
On May 9th, 2019, local radio stations Kiss 98.5 and WBEN hosted the annual Kiss Cares for Kids/ WBEN Radiothon to benefit Oishei Children’s Hospital. The entire radiothon raised over $208,000, surpassing the original $173,000 goal that would enable the hospital to purchase a new ENT Tower. Oishei Children’s Hospital provides state-of-the-art medical care to members of the Buffalo ...
By ONY Biotech
-
Honoring Ony’S Founder, Dr. Edmund Egan
Earlier this year, our founder and longtime Chief Medical Officer, Dr. Edmund Egan—known by many as Ted—announced his retirement after more than 37 years with the company. Dr. Egan was one of five scientists that founded ONY Biotech, then ONY, Inc., in 1985 in hopes of developing a lung surfactant to treat premature infants born with respiratory distress syndrome, known as RDS. A ...
By ONY Biotech
-
Study Results Are In On A Potential Non-Invasive Treatment For Rds
For little lungs everywhere, the families that love them, and the neonatologists who care for them, there’s news coming out of ONY Biotech, a family-focused neonatology pharmaceutical company. Today, ONY Biotech announced the results of a clinical trial on its aerosolized surfactant for newborns with respiratory distress syndrome (RDS), a disorder caused by lack of surfactant that can ...
By ONY Biotech
-
Aerogen Pharma Enters into Exclusive Agreements with Nuance Pharma to Advance Treatment of Respiratory Distress Syndrome in Premature Infants in China
Aerogen Pharma, a developer of innovative inhaled treatments for patients in critical care, and Nuance Pharma (“Nuance”), a specialty care focused biopharma with late-stage clinical programs and existing commercial operations, today announce an exclusive agreement to join forces in Greater China to develop a superior, non-invasive approach to treatment of RDS, a life-threatening ...
By Aerogen
-
Fab’entech, winner in an ambitious European programme, has been awarded 9.2 million euros to develop its treatment against Covid-19 and its variants.
The EPIC-CROWN-2 project, initiated by the Lyon-based biotech company, has received funding to the tune of 9.2 million euros from the European Commission. Thanks to this grant, awarded in the context of the first call for HERA projects (HERA is a new European authority dedicated to preparing and responding to health emergencies), Fab’entech will be able to accelerate the development of its ...
By Fab’entech
-
Oregon pesticide vendors violated laws aimed at protecting consumers from mishandling products
Three Oregon companies violated federal pesticide laws designed to protect consumers, according to three separate settlements with the U.S. Environmental Protection Agency. Nufarm Americas, Inc., Morrow County Grain Growers, Inc. and Grange Cooperative Supply Association will pay $127,000 for selling mislabeled pesticide products in Oregon. “When pesticides aren't handled properly they can ...
-
BioCardia Announces FDA Approval of Its IND for NK1R+ Mesenchymal Stem Cells for the Treatment of Patients Recovering from Acute Respiratory Distress due to COVID-19
BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational New Drug (IND) application for BCDA-04, a proprietary allogeneic mesenchymal cell (MSC) population that is Neurokinin-1 receptor positive ...
-
Orion Biotechnology Receives Funding to Test OB-002 for Treatment of COVID-19
Orion Biotechnology Canada Ltd., a clinical stage pharmaceutical company focused on precision engineering small protein therapeutics, today announced that it is receiving advisory services and conditional funding from the National Research Council Industrial Research Assistance Program (NRC IRAP), to support the development of Orion’s lead compound, OB-002, a promising treatment for ...
-
Eg Technology Select Three EIT Health Catapult Winners For Most Innovative Product
As a sponsor of the award, eg have offered a total of 10 days’ worth of engineering expertise, shared amongst the winning three applicants, that can be used towards the realisation of their innovation. The first prize was awarded to Leuko, who will receive five days’ worth of engineering and development support with the eg technology engineering specialists. Leuko have created ...
-
United States: EPA warns against use of mothballs that look like Candy
The U.S. Environmental Protection Agency (EPA) is warning the public about a potential threat from an illegal pesticide product uncovered during an inspection of a shipment at a warehouse in Kearny, NJ. EPA discovered that a Brooklyn-based company had attempted to import mothballs from China that could be mistaken for candy and are not registered with EPA, as required by federal law. These ...
-
Fretting Corrosion Causes Recall of Drug Delivery Medical Device
This past November, the U.S. Food and Drug Administration (FDA) announced a Class 1 recall of the Ikaria INOmax DS Drug Delivery System. The device is a drug delivery system used with ventilators to deliver a preset concentration of INOmax therapy gas (nitric oxide for inhalation) for critically ill patients. According to the FDA posting regarding the recall, “Fretting corrosion at the ...
-
BioCardia Reports Second Quarter 2021 Financial Results and Business Highlights
BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the second quarter of 2021 and filed its quarterly report on Form 10-Q for the three and six months ended June 30, 2021 with the Securities and Exchange Commission. Q2 and Recent Business Highlights: ...
-
IONICON Analyzers at the Forefront of International COVID-19 Testing Research
A non-invasive test for COVID-19 with instant results would be a gamechanger in the efforts against COVID-19. Breath analysis shows a great potential for a rapid, non-invasive detection of COVID-19 infections. Follow our journey around the world, where we shine a light on current research projects where IONICON PTR-TOF instruments are deployed fighting this global pandemic by testing breath for ...
-
Longeveron Announces Initiation of Phase 2a Clinical Trial of Lomecel-B for the Treatment of Alzheimer’s Disease
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and certain life-threatening conditions, announced today the initiation of its Phase 2a clinical trial evaluating Lomecel-B as a treatment for Alzheimer’s disease (AD). The first patient has consented to participate in the trial and ...
-
Longeveron Enters into Cooperative Research and Development Agreement with the US Department of Veterans Affairs for its Phase 2 Alzheimer’s Trial
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today a Cooperative Research and Development Agreement (CRADA) with the United States Department of Veterans Affairs (VA) for the addition of a Miami VA clinical site to its ongoing Phase 2 ...
-
New Research Demonstrates Clinical Utility of Daxor Corporation Blood Volume (BVA-100) Diagnostic in Neurocritical Care
Data Highlight Daxor’s Diagnostic Changes Care in 69% of Patients With Non-Traumatic Subarachnoid Hemorrhage (nSAH) Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announces new data demonstrating the clinical utility of the BVA-100 blood test in patients with non-traumatic subarachnoid hemorrhage (nSAH) presented at the virtual ...
-
Longeveron Announces Publication of Lomecel-B Phase 2b Trial Design in Journal of Frailty and Aging
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and certain life-threatening conditions, announced today publication of the design and rationale from its recently completed Phase 2b aging frailty clinical trial with Lomecel-B in the Journal of Frailty and Aging. This peer-reviewed ...
-
Seattle AVM Biotechnology announces second IND for AVM0703: clinical trial permitted to treat COVID-19 and Influenza ARDS with its “supercharged” version of dexamethasone
AVM Biotechnology has received FDA permission to proceed with clinical trials to evaluate its proprietary drug AVM0703 in the treatment of Acute Respiratory Distress Syndrome (ARDS) mediated by COVID-19 or Influenza patients. This is AVM’s second “safe to proceed” clinical trial authorization from the FDA within the past six months and demonstrates the broad potential of ...
-
Stemedica Signs License Agreement with Pulthera, LLC for all Respiratory Indications including those related to COVID-19
Stemedica Cell Technologies, Inc. (“Stemedica”), a San Diego-based biotech company specializing in the manufacture of clinical grade stem cells, announced today that it has signed a Licensing Agreement with Pulthera, LLC for the rights to use, distribute and sell its mesenchymal stem cell technologies in the treatment of COVID-19 and additional pulmonary conditions. The agreement was ...
-
Thirty-Four Governors Proclaim May 2007 for Awareness of Pollution and Chemical Induced Illnesses!
Thirty-seven proclamations for multiple chemical sensitivity (MCS), toxic injury (TI), or chemical sensitivity (CS) have been signed by governors of 34 states! This year’s proclamations represent the largest signing of any past year, indicating increased awareness of these debilitating environmental illnesses. Multiple chemical sensitivity is an environmental illness which causes negative ...
By MCS America
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you